Chimeric Therapeutics (ASX:CHM) FCF Margin %: 0.00% (As of Dec. 2025)


What is Chimeric Therapeutics FCF Margin %?

Chimeric Therapeutics ASX:CHM +1.47% FCF Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Chimeric Therapeutics ranks worse than 61.52% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Chimeric Therapeutics's Free Cash Flow for the six months ended in Dec. 2025 was A$-4.08 Mil. Chimeric Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Chimeric Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Chimeric Therapeutics's current FCF Yield % is -234.02%.

The historical rank and industry rank for Chimeric Therapeutics's FCF Margin % or its related term are showing as below:

ASX:CHM' s FCF Margin % Range Over the Past 10 Years
Min: -219.45   Med: -183.32   Max: -183.32
Current: -219.45

During the past 5 years, the highest FCF Margin % of Chimeric Therapeutics was -183.32%. The lowest was -219.45%. And the median was -183.32%.

ASX:CHM's FCF Margin % is ranked worse than
61.52% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs ASX:CHM: -219.45

Chimeric Therapeutics FCF Margin % Related Terms

Chimeric Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics FCF Margin % Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
FCF Margin %
0.00 0.00 0.00 0.00 -183.32

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:CHM vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Chimeric Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's FCF Margin % falls into.


Chimeric Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Chimeric Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-7.276/3.969
=-183.32 %

Chimeric Therapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-4.083/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Chimeric Therapeutics (ASX:CHM) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #590 out of 959 companies in the Biotechnology industry, placing it in the top 61.5%.
Is Chimeric Therapeutics' FCF Margin % too high?
Chimeric Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Chimeric Therapeutics ranks #590 out of 959 companies in the Biotechnology industry, which is below the industry midpoint.
How does Chimeric Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #590 out of 959 companies for FCF Margin %. This places Chimeric Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (ASX:CHM) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Chimeric Therapeutics (ASX:CHM), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.